Ann T. Farrell et al., 2016-04-08: FDA's approval letter for NDA 204630, ProvayBlue (methylene blue) injection 50 mg/10 mL, submitted by Provepharm SAS under section 505(b)(2); it grants accelerated approval for pediatric and adult acquired methemoglobinemia, effective 8 April 2016 (electronic signature page signed 04/08/2016 by Ann T. Farrell).
We have completed our review of this application, as amended. It is approved under the provisions of accelerated approval regulations (21 CFR 314.500), effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.
p.1 of 6 (PDF p.1)
Ann T. Farrell et al., 2016-04-08: FDA's approval letter for NDA 204630, ProvayBlue (methylene blue) injection 50 mg/10 mL, submitted by Provepharm SAS under section 505(b)(2); it grants accelerated approval for pediatric and adult acquired methemoglobinemia, effective 8 April 2016 (electronic signature page signed 04/08/2016 by Ann T. Farrell). Study type: regulatory record.
